GSK•benzinga•
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
Summary
GSK beat Q1 estimates with $9.46 billion in sales and $1.13 EPS, driven by strong Specialty Medicines and meningitis vaccine performance.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 30, 2025 by benzinga